Comparing the current results to its competitors, Orchestra Biomed Holdings Inc reported Revenue decrease in the 2 quarter 2026 year on year by -89.47 %, despite the revenue increase by the most of its competitors of 6.31 %, recorded in the same quarter.
Orchestra Biomed Holdings Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 35.84 %
Orchestra Biomed Holdings Inc 's Comment on Competition and Industry Peers
The company operates in the medical device industry, focusing on interventional cardiology and cardiac rhythm management. Competitors for Virtue SAB include Boston Scientific Corporation, Medtronic plc, Becton Dickinson, Philips N.V., B. Braun, Abbott Laboratories, Cordis, Teleflex, Inc., Concept Medical, Inc., MicroPort, Eurocor Tech GmbH, iVascular, S.L.U., Biosensors International Group, Ltd., Balton, and Invamed, Inc. For AVIM Therapy, competitors in cardiac rhythm management devices include Abbott Laboratories, Boston Scientific Corporation, and BIOTRONIK, Inc. Other competitors mentioned in company filings are Abbott Laboratories, B. Braun, Balton, Becton Dickinson, Biosensors International Group, Ltd., BIOTRONIK, Inc., Boston Scientific Corporation, Concept Medical, Inc., Cordis, Eurocor Tech GmbH, Invamed, Inc., iVascular, S.L.U., Medtronic plc, MicroPort, Philips N.V., and Teleflex, Inc.
March 6, 2024
Orchestra BioMed Holdings, Inc. recently conducted a clinical study to evaluate the efficacy of Atrioventricular Interval Modulation (AVIM) therapy, also known as BackBeat CNT, in pacemaker-indicated patients with uncontrolled hypertension. The study aimed to compare AVIM therapy with standard right ventricular (RV) pacing in terms of systolic blood pressure and overall cardiac function. The results of this pressure-volume (PV) loop study, conducted at Na Homolce Hospital in Prague under the supervision of Prof. Petr Neuil, M.D., were presented at the Technology and Heart Failure Therapeutics (THT) 2024 Meeting by Prof. Karl-Heinz Kuck, M.D., Medical Director at LANS Cardio Hamburg. Methodology:The PV loop s...
Boston Scientific Corporations business model centers on creating innovative medical devices for diverse specialties, aimed at addressing unmet medical needs and enhancing patient outcomes. The company sells its products to healthcare professionals and hospitals globally, supported by robust sales and distribution networks. It prioritizes research and development to continually introduce new technologies and solutions.
Baxter International Inc is a global healthcare company that specializes in providing a wide range of medical products and services. They operate through various business segments including Pharmaceuticals, Medical Products, and Renal Care, offering solutions for hospitals, clinics, and home-based healthcare settings.
Atricure Inc is a medical device company that focuses on developing, manufacturing, and selling innovative surgical solutions for the treatment of cardiac arrhythmias and other heart-related conditions.
Sources:
Orchestra Biomed Holdings Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Orchestra Biomed Holdings Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
